Orum Therapeutics, Inc. (KOSDAQ:475830)

Market Cap	1.90T +206.7%
Revenue (ttm)	23.56M -99.9%
Net Income	-41.97B
EPS	-2,017.00
Shares Out	21.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	156,184
Average Volume	193,154
Open	89,600
Previous Close	89,500
Day's Range	87,400 - 92,200
52-Week Range	15,950 - 146,600
Beta	n/a
RSI	46.52
Earnings Date	Apr 3, 2026

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It also develops multiple programs; and E3 Ligase-DAC...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 475830

Financial Performance

In 2025, Orum Therapeutics's revenue was 23.56 million, a decrease of -99.89% compared to the previous year's 20.91 billion. Losses were -41.97 billion, 631.2% more than in 2024.